The Name Change That Changed Everything
For decades, polycystic ovary syndrome was understood — by many patients, and even by some clinicians — primarily as a fertility condition. A condition you treated when you wanted to get pregnant, and perhaps set aside when you didn’t.
The renaming of PCOS to PMOS — polyendocrine metabolic ovarian syndrome — changes that framing fundamentally. The new name makes explicit what the science has been showing for years: this is a complex, multi-system condition with endocrine, metabolic, reproductive, psychological, and dermatological dimensions.
For women with PMOS, this matters enormously. Because understanding that PMOS is a whole-body condition — not just a fertility issue — is the foundation of the care you deserve.
The Metabolic Core of PMOS
The inclusion of ‘metabolic’ in the new name is not incidental. According to the Lancet paper that formalised the name change, metabolic abnormalities are central to PMOS from its genetic origins through to its clinical manifestations.
Insulin Resistance: The Metabolic Driver
Insulin resistance is present in the majority of women with PMOS — including approximately 75% of women with a healthy BMI. In insulin resistance, the body’s cells do not respond efficiently to insulin, causing the pancreas to produce more.
This excess insulin has a cascade of effects in PMOS:
- It stimulates the ovaries to produce excess androgens
- It disrupts follicle development and ovulation
- It promotes fat storage, particularly around the abdomen
- It contributes to elevated blood sugar and, over time, risk of type 2 diabetes
- It drives low-grade inflammation throughout the body
Addressing insulin resistance — through lifestyle modification, metformin, or other means — is one of the most impactful things a woman with PMOS can do for both her short-term symptoms and long-term health.
Type 2 Diabetes Risk
Women with PMOS have a significantly elevated risk of developing type 2 diabetes and impaired glucose tolerance, even at younger ages than typically seen in the general population. This risk is present regardless of weight, though it is exacerbated by obesity.
Regular glucose screening — ideally including a full oral glucose tolerance test — is recommended for all women with PMOS.
Cardiovascular Risk
The metabolic features of PMOS translate into elevated cardiovascular risk. Research shows that women with PMOS have higher odds of composite cardiovascular disease, myocardial infarction, and stroke compared to women without the condition.
Contributing factors include:
- Dyslipidaemia (abnormal cholesterol and triglycerides)
- Hypertension
- Insulin resistance and elevated blood sugar
- Low-grade chronic inflammation
- Metabolic dysfunction-associated steatotic liver disease (fatty liver), which is more common in PMOS
These risks underscore why PMOS management should include regular metabolic monitoring — not just at the time of fertility treatment, but throughout a woman’s life.
Hormonal Features Beyond Fertility
The endocrine features of PMOS extend beyond the reproductive years. Although ovulatory dysfunction and fertility challenges are most prominent during the reproductive years, the hormonal dysregulation underlying PMOS does not simply disappear after menopause.
Ongoing monitoring of androgen levels, insulin function, and metabolic markers is relevant throughout a woman’s life. The International Guidelines that govern PMOS management were recently updated to reflect this lifespan perspective.
Psychological Wellbeing and PMOS
The psychological burden of PMOS is one of the most underacknowledged aspects of the condition. Research consistently shows elevated rates of:
- Anxiety disorders
- Depression
- Body image disturbance
- Disordered eating
- Reduced overall quality of life
These psychological impacts are not simply a reaction to having a difficult diagnosis. There is evidence that the hormonal features of PMOS themselves — including elevated androgens and insulin dysregulation — have direct neurobiological effects that contribute to anxiety and depression.
The name change from PCOS to PMOS was, in part, motivated by the harm the old name was doing to patients’ mental health — particularly the stigma associated with a name that focused on reproductive organs and implied a fertility-defining condition.
For women with PMOS, seeking and receiving psychological support is a legitimate and important part of comprehensive care. Anxiety and depression in the context of PMOS are real, they are common, and they are treatable.
Dermatological Features and Body Image
Acne, hirsutism (excess hair growth), and alopecia (scalp hair loss) are common in PMOS and can have a profound impact on self-esteem and quality of life.
These features are driven primarily by elevated androgens and respond best to treatments that address the underlying hormonal cause, rather than purely symptomatic approaches. In clinical practice, this may include:
- Anti-androgen medications (such as spironolactone)
- Combined oral contraceptive pills (for women not actively trying to conceive)
- Metformin or insulin-sensitising agents
- Topical treatments for acne
- Hair removal treatments for hirsutism
- Hair restoration approaches for alopecia
It is worth acknowledging that the distress caused by these features is real and valid. PMOS-related skin and hair changes are not a cosmetic inconvenience — they are symptoms of a medical condition that deserve medical treatment.
PMOS Across the Lifespan
PMOS is a lifelong condition, and its manifestations shift across different life stages.
In adolescence
PMOS can present as irregular cycles (though some irregularity is normal in early puberty), acne, and signs of elevated androgens. Careful diagnosis in adolescents is important to avoid over-diagnosis while not missing a genuine condition.
In the reproductive years
Fertility, ovulation, and reproductive health are typically the primary concerns during these years. This is also when metabolic features often become more pronounced, particularly with lifestyle factors.
During pregnancy
Women with PMOS have elevated risks of gestational diabetes, pre-eclampsia, and preterm birth, and should receive additional monitoring during pregnancy.
Around perimenopause and beyond
The ovulatory features of PMOS may lessen as women approach menopause, but the metabolic and cardiovascular risk profile does not diminish. This is a critical time to ensure that women with PMOS are receiving appropriate cardiometabolic monitoring.
What Comprehensive PMOS Care Looks Like
Given the multi-system nature of PMOS, care should address all relevant dimensions — not just fertility:
- Regular metabolic screening: fasting glucose or glucose tolerance test, lipid profile, blood pressure, liver function
- Hormonal monitoring: androgens, LH, FSH, AMH
- Cardiovascular risk assessment: regular and from an early age
- Psychological support: routine screening for anxiety and depression, and access to appropriate support
- Lifestyle support: nutrition guidance, physical activity support, sleep and stress management
- Dermatological management: treatment of acne, hirsutism, and alopecia as needed
- Fertility planning: when relevant, specialist input on ovulation, treatment options, and pregnancy management
This is the kind of comprehensive, joined-up care that the name change from PCOS to PMOS is intended to support. When the condition is seen as a multi-system issue — not just a gynaecological one — care quality improves.
A Note on the Future of PMOS Research
One of the explicit goals of the name change is to improve research coherence and funding for this condition. When the name accurately reflects what the condition is, researchers can frame their questions better, funding bodies can allocate resources more appropriately, and clinical guidelines can be developed with a fuller understanding of what is being treated.
The 2026 Lancet publication notes that coordinated implementation is underway across health systems, research institutions, funding bodies, education providers, and disease classification systems globally. This includes engagement with the WHO for adoption in the International Classification of Diseases (ICD).
For women living with PMOS, this represents real progress — not just a name change, but the beginning of a more comprehensive, more accurate, and more compassionate approach to a condition that has long been underestimated.
Frequently Asked Questions: PMOS and Long-Term Health
Does PMOS increase the risk of cancer?
Women with PMOS have an elevated risk of endometrial cancer, primarily related to chronic anovulation and unopposed oestrogen exposure. This risk is manageable through appropriate hormonal management and monitoring. There is currently no clear evidence of elevated breast or ovarian cancer risk.
Should I be screened for diabetes if I have PMOS?
Yes. Women with PMOS should have regular glucose screening, ideally including an oral glucose tolerance test. This should begin at the time of diagnosis and be repeated regularly, even if initial tests are normal.
Does PMOS affect cardiovascular health?
Yes. Women with PMOS have elevated cardiovascular risk compared to women without the condition, related to metabolic features including insulin resistance, dyslipidaemia, and hypertension. Regular cardiometabolic monitoring is recommended from an early age.
Does PMOS go away after menopause?
The ovulatory and reproductive features of PMOS tend to become less prominent as women approach menopause. However, the underlying metabolic and hormonal features do not disappear, and monitoring of cardiovascular and metabolic health remains important throughout life.
Is the psychological impact of PMOS recognised in medical guidelines?
Yes. International guidelines for PMOS management explicitly address psychological wellbeing and recommend routine screening for anxiety and depression. Psychological support is considered a legitimate and important component of PMOS care.
Can lifestyle changes really make a difference to PMOS?
Yes — the evidence for lifestyle intervention in PMOS is strong. Improvements in diet, physical activity, sleep, and stress management can meaningfully improve insulin sensitivity, reduce androgen levels, restore ovulation, improve mood, and reduce long-term metabolic risk. Lifestyle support should be part of every PMOS management plan.
Disclaimer: This content is for educational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before making decisions about fertility treatment.
About the Author
Leigh-Ann Geydien is the founder of Fertility Solutions, South Africa’s only dedicated fertility directory. With a deep commitment to patient advocacy, she built the platform to bridge the gap between those navigating fertility challenges and the clinics and reproductive health specialists best placed to help them.
